Rallybio Reveals Details of Two Pipeline Programs with the Potential to Transform the Lives of Patients with Rare Diseases
Press release content from Business Wire. The AP news staff was not involved in its creation. Rallybio Reveals Details of Two Pipeline Programs with the Potential to Transform the Lives of Patients with Rare Diseases March 2, 2021 GMT NEW HAVEN, Conn.--(BUSINESS WIRE)--Mar 2, 2021-- Rallybio, a clinical-stage biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders, today announced the details of two previously undisclosed pipeline programs. RLYB212 is a novel monoclonal antibody to human pla...